Who We Are

We aim to improve patient outcomes and restore quality of life for patients suffering from venous thromboembolism (VTE).

Innovating Next-Gen Solutions for Venous Thromboembolism

Akura Medical is a medical technology company dedicated to addressing venous thromboembolism (VTE). Our flagship product, the Katana™ Thrombectomy System, is poised to redefine pulmonary embolism (PE) treatment standards by enabling enhanced removal of diverse clot types more efficiently. The Katana Thrombectomy System embodies our dedication to revolutionizing VTE treatment. Join us in our mission to reshape the landscape of VTE care and make a lasting impact on the lives of patients worldwide.

Powered by Shifamed

At Akura Medical, we are privileged to be a Shifamed portfolio company, a highly specialized medical innovation hub. With access to Shifamed’s resources and support, we can efficiently move from concept to large scale production of advanced solutions and get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.

Leadership

Innovation is a collaborative journey, meet our leadership team.

  • Amr Salahieh

    |

    Chair & Acting CEO

    Amr Salahieh

    |

    Chair & Acting CEO

  • Kavi Vyas

    Kavi Vyas

    |

    Chief Commercial and Clinical Officer

    Kavi Vyas

    |

    Chief Commercial and Clinical Officer

  • Aadel Al-Jadda

    |

    Co-Founder & VP of R&D

    Aadel Al-Jadda

    |

    Co-Founder & VP of R&D

  • Theresa Brandner

    Theresa Brandner

    |

    Vice President, Regulatory Affairs

    Theresa Brandner

    |

    Vice President, Regulatory Affairs

  • Praveen Dala

    |

    Vice President, Console

    Praveen Dala

    |

    Vice President, Console

  • Joann Heberer

    |

    Senior Vice President, QA

    Joann Heberer

    |

    Senior Vice President, QA

  • Faisal Khan

    |

    Senior Director, Marketing

    Faisal Khan

    |

    Senior Director, Marketing

  • Eric Lang

    |

    Vice President, Operations

    Eric Lang

    |

    Vice President, Operations

Press Releases

Akura Medical’s hub for the latest advancements in VTE treatment.

  • Akura Medical, a Shifamed Portfolio Company, Closes $53 Million in Series C Financing

    Dec 1, 2025

  • First Patient Enrolled In Akura Medical’s Us Pivotal Trial For Pulmonary Embolism

    Feb 4, 2025

  • Akura Medical Secures FDA Approval for US Pivotal Trial in Pulmonary Embolism

    Nov 4, 2024